Evon Poon

2.9k total citations
24 papers, 1.1k citations indexed

About

Evon Poon is a scholar working on Molecular Biology, Neurology and Cancer Research. According to data from OpenAlex, Evon Poon has authored 24 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 16 papers in Neurology and 9 papers in Cancer Research. Recurrent topics in Evon Poon's work include Neuroblastoma Research and Treatments (16 papers), Cancer, Hypoxia, and Metabolism (9 papers) and Virus-based gene therapy research (3 papers). Evon Poon is often cited by papers focused on Neuroblastoma Research and Treatments (16 papers), Cancer, Hypoxia, and Metabolism (9 papers) and Virus-based gene therapy research (3 papers). Evon Poon collaborates with scholars based in United Kingdom, United States and Germany. Evon Poon's co-authors include Margaret Ashcroft, Louis Chesler, Adrian L. Harris, Martin Eilers, Anne Carstensen, Yann Jamin, Simon P. Robinson, Richard Bayliss, Selena G. Burgess and Mark W. Richards and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Nature Communications.

In The Last Decade

Evon Poon

23 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Evon Poon United Kingdom 14 789 338 334 303 173 24 1.1k
Ulrica Westermark Sweden 11 682 0.9× 292 0.9× 212 0.6× 285 0.9× 50 0.3× 19 984
Natalie Meyer Canada 5 1.2k 1.5× 337 1.0× 101 0.3× 351 1.2× 106 0.6× 7 1.5k
Jon S. Zawistowski United States 17 603 0.8× 133 0.4× 666 2.0× 206 0.7× 157 0.9× 28 1.5k
Taru Muranen United States 13 555 0.7× 177 0.5× 97 0.3× 383 1.3× 290 1.7× 25 1.1k
Karina J. Yoon United States 18 777 1.0× 168 0.5× 152 0.5× 409 1.3× 63 0.4× 48 1.1k
Xing-Jun Cao United States 12 793 1.0× 184 0.5× 70 0.2× 255 0.8× 102 0.6× 14 1.1k
Lucia Borriello United States 16 474 0.6× 274 0.8× 136 0.4× 373 1.2× 72 0.4× 27 984
Marco Lodrini Germany 16 885 1.1× 178 0.5× 219 0.7× 299 1.0× 46 0.3× 24 1.1k
Ronald M. Paranal United States 11 1.8k 2.3× 300 0.9× 88 0.3× 480 1.6× 82 0.5× 17 2.2k
Constadina Arvanitis United States 11 1.3k 1.7× 422 1.2× 59 0.2× 637 2.1× 241 1.4× 21 1.9k

Countries citing papers authored by Evon Poon

Since Specialization
Citations

This map shows the geographic impact of Evon Poon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Evon Poon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Evon Poon more than expected).

Fields of papers citing papers by Evon Poon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Evon Poon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Evon Poon. The network helps show where Evon Poon may publish in the future.

Co-authorship network of co-authors of Evon Poon

This figure shows the co-authorship network connecting the top 25 collaborators of Evon Poon. A scholar is included among the top collaborators of Evon Poon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Evon Poon. Evon Poon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhang, James, Monica Faronato, Wouter W. Kallemeijn, et al.. (2025). MYC deregulation sensitizes cancer cells to N-myristoyltransferase inhibition. Cell Reports. 44(9). 116180–116180.
2.
Hu, Yubing, Rassim Khelifa, Amina Ali, et al.. (2025). Diagnostic technologies for neuroblastoma. Lab on a Chip. 25(15). 3630–3664. 1 indexed citations
3.
Poon, Evon, et al.. (2025). Oxphos targeting of MYCN-amplified neuroblastoma. Frontiers in Oncology. 15. 1613751–1613751. 1 indexed citations
4.
Kollareddy, Madhu, Marianna Szemes, Evon Poon, et al.. (2024). Spliceosomal vulnerability of MYCN-amplified neuroblastoma is contingent on PRMT5-mediated regulation of epitranscriptomic and metabolomic pathways. Cancer Letters. 604. 217263–217263. 1 indexed citations
5.
Ferguson, Kirsty M., Evon Poon, Laura M. Woods, et al.. (2023). Palbociclib releases the latent differentiation capacity of neuroblastoma cells. Developmental Cell. 58(19). 1967–1982.e8. 12 indexed citations
6.
Carregari, Victor Corasolla, Martina Morini, Alessandra Eva, et al.. (2021). MYC regulates metabolism through vesicular transfer of glycolytic kinases. Open Biology. 11(12). 210276–210276. 9 indexed citations
7.
Urban‐Wójciuk, Zuzanna, Amy C. Graham, Karen Barker, et al.. (2021). The biguanide polyamine analog verlindamycin promotes differentiation in neuroblastoma via induction of antizyme. Cancer Gene Therapy. 29(7). 940–950. 4 indexed citations
8.
Poon, Evon, Matthew Clarke, Neil P. Jerome, et al.. (2020). Noninvasive MRI Native T1 Mapping Detects Response to MYCN -targeted Therapies in the Th- MYCN Model of Neuroblastoma. Cancer Research. 80(16). 3424–3435. 21 indexed citations
9.
George, Sally L., Virinder S. Parmar, Federica Lorenzi, et al.. (2020). Novel therapeutic strategies targeting telomere maintenance mechanisms in high-risk neuroblastoma. Journal of Experimental & Clinical Cancer Research. 39(1). 78–78. 37 indexed citations
10.
King, David S., Gilberto S. Almeida, Colin Kwok, et al.. (2020). MYCN expression induces replication stress and sensitivity to PARP inhibition in neuroblastoma. Oncotarget. 11(23). 2141–2159. 23 indexed citations
11.
Tucker, Elizabeth R., Evon Poon, & Louis Chesler. (2019). Targeting MYCN and ALK in resistant and relapsing neuroblastoma. Cancer Drug Resistance. 2(3). 803–812. 10 indexed citations
12.
Zeid, Rhamy, Matthew A. Lawlor, Evon Poon, et al.. (2018). Enhancer invasion shapes MYCN-dependent transcriptional amplification in neuroblastoma. Nature Genetics. 50(4). 515–523. 129 indexed citations
13.
Doro, Daniel, Evon Poon, Elizabeth R. Tucker, et al.. (2018). Glycogen synthase kinase 3 controls migration of the neural crest lineage in mouse and Xenopus. Nature Communications. 9(1). 1126–1126. 34 indexed citations
14.
Büchel, Gabriele, Anne Carstensen, Eoin Leen, et al.. (2017). Association with Aurora-A Controls N-MYC-Dependent Promoter Escape and Pause Release of RNA Polymerase II during the Cell Cycle. Cell Reports. 21(12). 3483–3497. 60 indexed citations
15.
Dolman, M. Emmy M., Evon Poon, Marli E. Ebus, et al.. (2015). Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma. Clinical Cancer Research. 21(22). 5100–5109. 47 indexed citations
16.
Brockmann, Markus, Evon Poon, Anne Carstensen, et al.. (2013). Small Molecule Inhibitors of Aurora-A Induce Proteasomal Degradation of N-Myc in Childhood Neuroblastoma. Cancer Cell. 24(1). 75–89. 223 indexed citations
17.
Jamin, Yann, Elizabeth R. Tucker, Evon Poon, et al.. (2012). Evaluation of Clinically Translatable MR Imaging Biomarkers of Therapeutic Response in the TH-MYCNTransgenic Mouse Model of Neuroblastoma. Radiology. 266(1). 130–140. 24 indexed citations
18.
Yang, Jun, Oliver Staples, Luke W. Thomas, et al.. (2012). Human CHCHD4 mitochondrial proteins regulate cellular oxygen consumption rate and metabolism and provide a critical role in hypoxia signaling and tumor progression. Journal of Clinical Investigation. 122(2). 600–611. 77 indexed citations
19.
Jamin, Yann, Lynette A. Smyth, Simon P. Robinson, et al.. (2010). Noninvasive detection of carboxypeptidase G2 activity in vivo. NMR in Biomedicine. 24(4). 343–350. 9 indexed citations
20.
Poon, Evon, Adrian L. Harris, & Margaret Ashcroft. (2009). Targeting the hypoxia-inducible factor (HIF) pathway in cancer. Expert Reviews in Molecular Medicine. 11. e26–e26. 171 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ulrica Westermark Breakdown of academic impact, for papers by Natalie Meyer Breakdown of academic impact, for papers by Jon S. Zawistowski Breakdown of academic impact, for papers by Taru Muranen Breakdown of academic impact, for papers by Karina J. Yoon Breakdown of academic impact, for papers by Xing-Jun Cao Breakdown of academic impact, for papers by Lucia Borriello Breakdown of academic impact, for papers by Marco Lodrini Breakdown of academic impact, for papers by Ronald M. Paranal Breakdown of academic impact, for papers by Constadina Arvanitis
Rankless by CCL
2026